Modulation of TGF-β signaling new approaches toward kidney disease and fibrosis therapy

Area of Science:

• Nephrology
• Molecular Biology
• Translational Medicine

Background:

• Chronic kidney disease (CKD) prevalence is rising globally, with limited effective therapies.
• Kidney fibrosis, marked by extracellular matrix deposition, drives CKD progression.
• Transforming growth factor-beta (TGF-β) is a key mediator of kidney fibrosis.

Purpose of the Study:

• To review kidney cell-specific effects of TGF-β signaling in CKD.
• To discuss challenges in targeting TGF-β therapeutically for CKD.
• To propose alternative strategies for targeting TGF-β signaling in CKD therapy.

Main Methods:

• Literature review of TGF-β signaling pathways in kidney fibrosis.
• Analysis of challenges in clinical translation of TGF-β inhibitors.
• Exploration of selective TGF-β signaling modulation strategies.

Main Results:

• TGF-β signaling is crucial but pleiotropic, complicating direct inhibition.
• Broad TGF-β blockade faces challenges due to its role in organ homeostasis.
• Selective modulation of TGF-β signaling pathways presents a viable therapeutic avenue.

Conclusions:

• Targeting TGF-β is critical for treating kidney fibrosis in CKD.
• Fine-tuning TGF-β inhibition via selective modulators may overcome current therapeutic limitations.
• This approach could lead to safer and more effective CKD treatments.